

# Pharmacy Prior Authorization Form

For Prior Authorization, please fax to: 877 974-4411 toll free, or 616 942-8206

This form applies to:  **Commercial (Traditional)**       **Commercial (Individual/Optimized)**

**Medicaid**

This request is:  **Urgent** (life threatening)     **Non-Urgent** (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

## Subsys<sup>®</sup> (fentanyl citrate spray)

### Member

Last Name: \_\_\_\_\_

First Name: \_\_\_\_\_

ID #: \_\_\_\_\_

DOB: \_\_\_\_\_ Gender: \_\_\_\_\_

Primary Care Physician: \_\_\_\_\_

Requesting Provider: \_\_\_\_\_

Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_

Provider Address: \_\_\_\_\_

Provider NPI: \_\_\_\_\_

Contact Name: \_\_\_\_\_

Provider Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Product Information

- Drug product:
- Subsys 100 mcg spray
  - Subsys 200 mcg spray
  - Subsys 400 mcg spray
  - Subsys 600 mcg spray
  - Subsys 800 mcg spray
  - Subsys 1,200 mcg spray
  - Subsys 1,600 mcg spray

**Start date** (or date of next dose): \_\_\_\_\_

**Date of last dose** (if applicable): \_\_\_\_\_

**Dosing frequency:** \_\_\_\_\_

### Precertification Requirements

Before this drug is covered, the patient must meet all of the following requirements:

1. This drug is being used to manage breakthrough pain in cancer patients already receiving and tolerant to around-the-clock opioid therapy for persistent cancer pain
2. Age 18 or older

Note: Patients are considered opioid tolerant when taking oral morphine 60 mg/day or more, transdermal fentanyl 25 mcg/hr, oral oxycodone 30 mg/day, oral hydromorphone 8 mg/day, oral oxymorphone 25 mg/day, oral hydrocodone 60mg/day, or an equianalgesic dose of another opioid for 1 week or longer.

**Note:** Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

**Priority Health Precertification Documentation**

**1. What condition is this drug being requested for?**

Breakthrough cancer pain

*Cancer diagnosis:* \_\_\_\_\_

Other – the patient’s condition is: \_\_\_\_\_

*Rationale for use:* \_\_\_\_\_

**2. What is the patient’s current opioid treatment (must be around-the-clock opioids for persistent cancer pain):**

Drug	Dose	Dates
_____	_____	_____
_____	_____	_____

**3. What other breakthrough pain medications have been tried?**

Drug	Dose	Dates
_____	_____	_____
_____	_____	_____
_____	_____	_____

**4. Please provide other rationale for use, if necessary:**

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_